MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy

Authors :: Jue Wang
Jinhuan Xu
Weigang Li
Yi Xiao
Jin Wang
Cheng He
Jianfeng Zhou
Min Xiao
Liang Huang
Meilan Zhang
Kefeng Shen
Jiachen Wang
Qinlu Li
Yuqi Guan
Liting Chen
Zhen Shang
Wei Zhang
Na Wang
Li Yang
Source :: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Publication Year :: 2021
Publisher :: BMJ, 2021.
Abstract: Immunotherapy has become one of the most effective treatments for refractory/relapsed (r/r) B cell lymphoma.[1][1] In particular, chimeric antigen receptor (CAR) T cell immunotherapy has recently been found to be a highly effective treatment for r/r diffuse large B cell lymphoma (DLBCL).[2][2] High

Subjects :: Adult
Male
0301 basic medicine
Cancer Research
medicine.medical_treatment
Immunology
Immunotherapy, Adoptive
Proto-Oncogene Proteins c-myc
03 medical and health sciences
0302 clinical medicine
Refractory
immune system diseases
hemic and lymphatic diseases
medicine
Humans
Immunology and Allergy
Antigenic Drift and Shift
RC254-282
B cell
Pharmacology
Receptors, Chimeric Antigen
business.industry
High grade B-cell lymphoma
Genetic Variation
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Immunotherapy
medicine.disease
BCL6
Chimeric antigen receptor
030104 developmental biology
medicine.anatomical_structure
Proto-Oncogene Proteins c-bcl-2
Oncology
030220 oncology & carcinogenesis
Disease Progression
Proto-Oncogene Proteins c-bcl-6
Cancer research
Molecular Medicine
Lymphoma, Large B-Cell, Diffuse
Tumor Suppressor Protein p53
Car t cells
business
Diffuse large B-cell lymphoma
Gene Deletion

Full Text Access

Tools